Ann Dermatol.  2018 Oct;30(5):575-580. 10.5021/ad.2018.30.5.575.

Evaluation of the Interventional Approaches in the Management of Cutaneous Leishmaniasis in Jazan: An Observational Study

• Makeen HA
• Buraik MA
• Menachery
• Alattas KM
• Meraya AM

• KMID: 2419748
• DOI: http://doi.org/10.5021/ad.2018.30.5.575

Abstract

BACKGROUND
Cutaneous leishmaniasis is a tropical infection of public health importance. Numerous treatment approaches are in practice with variable degree of success however its management has no universal consensus or practice guidelines to follow.
OBJECTIVE
Analyze the management of cutaneous leishmaniasis retrospectively at a central hospital of Jazan Province, Kingdom of Saudi Arabia to identify the current treatment pattern and compare the outcomes.
METHODS
This cross-sectional study was conducted based on the hospital records of patients who attended the dermatology clinic for cutaneous leishmaniasis during the year 2012 to 2015.
RESULTS
Forty three patients were included in the study. There was a male preponderance (65.1%) among the patients and 60.5% of them were of pediatric age group. Monotherapy was the initial choice for 58.1% of the patients. Intralesional sodium stibogluconate (SS-IL) was the most preferred treatment for initial therapy, as monotherapy and as part of combination therapy. A complete response was achieved in 22 patients (51.2%) with initial therapy. Among the different treatment groups, SS-IL+itraconazole showed significantly higher complete response rate compared to other treatments offered as initial therapy (p<0.01). Initial SS-IL monotherapy provided complete response in 41.2% patients receiving it, while itraconazole monotherapy provided complete response in 75% and 90.9% of the patients receiving initial itraconazole+SS-IL combination therapy with achieved complete response.
CONCLUSION
The findings and observations suggest that initial combination therapy with SS-IL+itraconazole significantly improved the complete response rates and thus reduced the need for additional or prolonged therapies.

Keyword

Cutaneous leishmaniasis; Intralesional injections; Itraconazole; Leishmania major; Leishmania tropica

MeSH Terms

Antimony Sodium Gluconate
Consensus
Cross-Sectional Studies
Dermatology
Hospital Records
Humans
Injections, Intralesional
Itraconazole
Leishmania major
Leishmania tropica
Leishmaniasis, Cutaneous*
Male
Observational Study*
Public Health
Retrospective Studies
Saudi Arabia
Antimony Sodium Gluconate
Itraconazole

Reference

1. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005; 366:1561–1577. PMID: 16257344.

2. Salam N, Al-Shaqha WM, Azzi A. Leishmaniasis in the middle east: incidence and epidemiology. PLoS Negl Trop Dis. 2014; 8:e3208. PMID: 25275483.

3. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7:581–596. PMID: 17714672.

4. Galgamuwa LS, Sumanasena B, Yatawara L, Wickramasinghe S, Iddawela D. Clinico-epidemiological patterns of cutaneous leishmaniasis patients attending the Anuradhapura Teaching Hospital, Sri Lanka. Korean J Parasitol. 2017; 55:1–7. PMID: 28285499.

5. Hepburn NC. Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infect Ther. 2003; 1:563–570. PMID: 15482153.

6. Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old world cutaneous leishmaniasis: diagnosis and treatment. J Dermatol Case Rep. 2013; 30:31–41.

7. Khan W, Zakai HA. Epidemiology, pathology and treatment of cutaneous leishmaniasis in taif region of Saudi Arabia. Iran J Parasitol. 2014; 9:365–373. PMID: 25678921.

8. al-Zahrani MA, Peters W, Evans DA, Smith V, Ching Chin I. Leishmania infecting man and wild animals in Saudi Arabia. 6. Cutaneous leishmaniasis of man in the south-west. Trans R Soc Trop Med Hyg. 1989; 83:621–628. PMID: 2617623.

9. Aoun K, Bouratbine A. Cutaneous leishmaniasis in North Africa: a review. Parasite. 2014; 21:14. PMID: 24626301.

10. World Health Organization. Leishmaniasis [Internet]. Geneva: World Health Organization;2012. cited 2014 Dec 17. Available from: http://www.who.int/leishmaniasis/burden/en/.

11. Rodríguez N, Guzman B, Rodas A, Takiff H, Bloom BR, Convit J. Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization. J Clin Microbiol. 1994; 32:2246–2252. PMID: 7814554.

12. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004; 53:158–166. PMID: 14729756.

13. Faris RM, Jarallah JS, Khoja TA, Al-Yamani MJ. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol. 1993; 32:610–612. PMID: 8407083.

14. Tallab TM, Bahamdam KA, Mirdad S, Johargi H, Mourad MM, Ibrahim K, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol. 1996; 35:594–597. PMID: 8854166.

15. Asilian A, Jalayer T, Nilforooshzadeh M, Ghassemi RL, Peto R, Wayling S, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ. 2003; 81:353–359. PMID: 12856053.

16. Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar, Moghiman T, Ashraf H, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. J Parasitol Res. 2011; 2011:656523. PMID: 22174993.

17. Bumb RA, Prasad N, Khandelwal K, Aara N, Mehta RD, Ghiya BC, et al. Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India. Br J Dermatol. 2013; 168:1114–1119. PMID: 23298394.

18. Asilian A, Sharif A, Faghihi G, Enshaeieh Sh, Shariati F, Siadat AH. Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004; 43:736–738. PMID: 15485530.

19. Gardlo K, Horska Z, Enk CD, Rauch L, Megahed M, Ruzicka T, et al. Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol. 2003; 48:893–896. PMID: 12789181.

20. El-Sayed M, Anwar AE. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J Eur Acad Dermatol Venereol. 2010; 24:335–340. PMID: 19744259.

21. Moosavi Z, Nakhli A, Rassaii S. Comparing the efficiency of topical paromomycine with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol. 2005; 44:1064–1065. PMID: 16409282.

22. Al-Jaser MH. Treatment trends of cutaneous leishmaniasis in Saudi Arabia. Saudi Med J. 2005; 26:1220–1224. PMID: 16127517.

23. Sharma NL, Mahajan VK, Kanga A, Sood A, Katoch VM, Mauricio I, et al. Localized cutaneous leishmaniasis due to leishmania donovani and leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in himachal pradesh, India. Am J Trop Med Hyg. 2005; 72:819–824. PMID: 15964970.

24. Feiz-Haddad MH, Kassiri H, Kasiri N, Panahandeh A, Lotfi M. Prevalence and epidemiologic profile of acute cutaneous leishmaniasis in an endemic focus, Southwestern Iran. J Acute Dis. 2015; 4:292–297.

25. Zaraa I, Ishak F, Kort R, El Euch D, Mokni M, Chaker E, et al. Childhood and adult cutaneous leishmaniasis in Tunisia. Int J Dermatol. 2010; 49:790–793. PMID: 20618499.

26. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by leishmania major. N Engl J Med. 2002; 346:891–895. PMID: 11907288.